Isomorphic Labs, Alphabet’s AI-driven drug discovery company spun out from Google DeepMind, has raised $600 million in its first-ever external funding round.
The raise was led by Thrive Capital, with participation from GV (Google Ventures) and Alphabet itself.
Accelerating AI-Driven Drug Design
The funding will help scale Isomorphic’s AI drug design platform and support its mission to bring AI-discovered therapeutics into clinical trials. The company leverages cutting-edge tools like AlphaFold, DeepMind’s AI model that accurately predicts the 3D structure of proteins—a breakthrough in computational biology.
Founded in 2021 by DeepMind co-founder Demis Hassabis, Isomorphic Labs aims to use AI not just to assist scientists, but to be central in designing new medicines faster, more efficiently, and with fewer failures.
“We didn’t need the capital,” Hassabis told the New York Times, “but this gives us room to bring in the best scientific talent and accelerate our mission.”
Advertisement
Big Pharma Partnerships and Nobel-Winning Science
Last year, Isomorphic Labs signed strategic collaborations with Eli Lilly and Novartis, which could yield up to $3 billion in milestone payments, signaling strong industry confidence in the platform’s potential.
Hassabis and DeepMind researcher John Jumper also received a 2024 Nobel Prize in Chemistry for their work on AlphaFold, underlining the scientific significance behind the company’s approach.
With fresh backing and groundbreaking science, Isomorphic Labs is now positioned at the forefront of a new era in AI-led pharmaceutical innovation.
